opnurasib,jdq443,tislelizumab
novartis,beigene
['kontrast-01', 'jdq443', 'lcsm,(-blcsm)']
avm: kontrast-01 jdq443 novel kras g12c. inhibitor
preliminary orr 57.1% at dose expansion dose
toxicity profile as expected, ongoing studies with icis and other combinations in 1l and 2l+ are ongoing and will reveal it's role among the other kras g12c inhibitors
#lcsm #asco23 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.